Sarepta Therapeutics Appoints Stephen L. Mayo to Its Board of Directors
November 17, 2021 at 08:30 am EST
Share
Sarepta Therapeutics, Inc. announced the appointment of Stephen L. Mayo, Ph.D., to its Board of Directors, effective immediately. Dr. Mayo is currently the Bren Professor of Biology and Chemistry at California Institute of Technology (Caltech), and serves on the board of directors for Merck and on the scientific advisory board of Rubryc Therapeutics. At Caltech, Dr. Mayo holds joint appointments in the Division of Biology and Biological Engineering and the Division of Chemistry and Chemical Engineering. He joined the Caltech faculty in 1992 and served as Vice Provost for Research from 2007 to 2010 and Chair of the Division of Biology and Biological Engineering from 2010 to 2020. Dr. Mayo's research focuses on the development of computational approaches to protein engineering ? a field that has broad applications ranging from advanced biofuels to human therapeutics. In 2004, he was elected to the U.S. National Academy of Sciences for his pioneering contributions in the field of protein design. Dr. Mayo has co-founded several companies: Molecular Simulations Inc. (now Biovia), Xencor, and Protabit, where he serves on the scientific advisory board. In addition to his academic and private-sector work, Dr. Mayo has served as an elected Board Member at the American Association for the Advancement of Science (2010-2014) and served as a presidential appointee to National Science Foundation?s National Science Board (2013-2018). Dr. Mayo received an undergraduate degree in chemistry from the Pennsylvania State University, and a Ph.D. in chemistry from Caltech. He completed postdoctoral work at both UC Berkeley and the Stanford University School of Medicine.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
SAREPTA THERAPEUTICS, INC. 
